Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

Video

In Partnership With:

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discussesthe updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

An important product that is getting a lot of attention is JNJ-4528, which was examined in the CARTITUDE-1 study, says Shah. JNJ-4528 is a BCMA-targeting CAR T-cell product that differs from idecabtagene vicleucel (ide-cel; bb2121), which also targets BCMA. The former targets 2 aspects of the BCMA protein; as such, it potentially changes some kinetics and how it interacts with the target myeloma cell.

The original data with JNJ-4528 in a small cohort of 29 patients who received treatment were presented at the 2019 ASH Annual Meeting and an impressive ORR of 100% was reported, according to Shah. Similar efficacy had been seen in the preliminary and mature data from the Chinese study with the same product, adds Shah. The CARTITUDE-1 study enrolled an American patient population and, similar to the ide-cel study, patients also had to have received 3 prior lines of therapy or at least have had prior exposure to a proteasome inhibitor, an immunomodulatory agent, or an anti-CD38 antibody. As such, the studies have very similar patient characteristics, notes Shah.

During the 2020 ASCO Virtual Scientific Program, additional data from CARTITUDE-1 were presented and showed that the ORR was still 100% and 86% of patients had a complete response (CR) or stringent CR, which is impressive in such an advanced, heavily pretreated patient population, says Shah. Investigators did not have evaluable data for progression-free survival yet; however, 86% of patients were progression free at 9 months, which is possibly superior to what was seen at the 12-month mark with ide-cel, notes Shah. While not condoning comparing the 2 trials, that is a reason why these data are so anticipated, concludes Shah.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,